(2)
ANN ARBOR, MI / ACCESSWIRE / December 23, 2020 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS
®), has recently been issued Chinese Patent ZL 2018 8 00500526 (the 526 patent) entitled Method and System for Estimating Fractional Fat Content of an Object from the Chinese Intellectual Property Office (SIPO).
This is the eighth Chinese patent issued to ENDRA for its TAEUS technology. ENDRA s intellectual property (IP) portfolio currently stands at 78 assets, including those in preparation, filed, issued and licensed. The 526 patent strengthens IP protection for our proprietary approach to assessing fat content in tissue. Our TAEUS system provides a non-invasive assessment of liver fat, which is particularly important in China where an estimated 30% of its 1.4 billion citizens are affected by Non-Alcoholic Fatty Liver Disease (NAFLD), said Francois Michelon, ENDRA s chief executive officer.
ENDRA Life Sciences Issued Chinese Patent for Its TAEUS(R) Platform Technology to Calculate Fat Concentration in Tissue
albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
ENDRA Life Sciences Granted Seventh Chinese Patent for its TAEUS(R) Platform Technology
albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
(2)
Now Has 78 Patents Issued, Filed, Licensed or in Preparation As Taeus Commercial Launch Plans Advance
ANN ARBOR, MI / ACCESSWIRE / December 15, 2020 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS
®), has recently been issued Chinese Patent ZL 2016 8 00267062 (the 062 patent) entitled Systems and Methods for Imaging Biological Tissue Structures from the Chinese Intellectual Property Office (SIPO). This is the seventh Chinese patent issued to ENDRA for its TAEUS technology. ENDRA s goal is to develop applications for our proprietary TAEUS technology in areas of high unmet clinical need and for which there are no practical existing tools. The recently issued 062 patent provides more robust intellectual property (IP) protection for our TAEUS platform in a key global market where an estimated 30% of its 1.4 billion citizens are affected by Non-Alcoholic Fatty Liver Disease, said Francois Michelon, ENDRA s chief exec